09:32:13 EST Tue 11 Dec 2018
Enter Symbol
or Name

Login ID:

Q:CELG - Celgene Corporation - http://www.celgene.com09:32:13 EST
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CELG - Q0.569.41 · 69.680.268.684.933572    110.81  66.6209:12:36Dec 1015 min RT 2¢

Recent Trades - Last 10 of 72
Time ETExPriceChangeVolume

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2018-12-10 07:20U:CELGNews ReleaseReport: Developing Opportunities within Avangrid, GoDaddy, NGL Energy Partners LP, Lazard, Briggs & Stratton, and Celgene — Future Expectations, Projections Moving into 2019
2018-12-03 19:30U:CELGNews ReleaseCelgene Corporation Announces Initial Clinical Data from Ongoing Phase 1/2 Evolve Trial with Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma at ASH 2018
2018-12-02 19:35U:CELGNews ReleaseCelgene Corporation Announces Results of AUGMENT Evaluating REVLIMID ® In Combination with Rituximab (R2) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018
2018-12-02 19:30U:CELGNews Releasebluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
2018-12-02 17:00U:CELGNews ReleaseCelgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session
2018-12-02 10:35U:CELGNews ReleaseCelgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018
2018-12-01 17:00U:CELGNews ReleaseCelgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018
2018-11-27 07:30U:CELGNews ReleaseCelgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma
2018-11-14 07:58U:CELGNews ReleaseLyfebulb Partners with Celgene to Inspire Patient-Driven Innovation in the Management of Multiple Sclerosis